非酒精性脂肪性肝病大鼠肝组织Vaspin表达及其意义探讨*

doi:10.3969/j.issn.1672-5069.2020.02.005

实用肝脏病杂志 ›› 2020, Vol. 23 ›› Issue (2): 167-170.doi: 10.3969/j.issn.1672-5069.2020.02.005

非酒精性脂肪性肝病大鼠肝组织Vaspin表达及其意义探讨^*

姜佳丽, 李莉, 赵菲, 钟乐萍, 郭子皓, 张川, 展玉涛

100730 北京市首都医科大学附属北京同仁医院消化内科(姜佳丽,李莉,赵菲,郭子皓,张川,展玉涛);感染病科(钟乐萍)

收稿日期:2019-03-29 出版日期:2020-03-10 发布日期:2020-04-20
通讯作者: 展玉涛, E-mail:yutaozhan@263.com
作者简介:姜佳丽,女,43岁,医学硕士,主治医师。主要从事胃肠道动力障碍性疾病与肝病学研究。E-mail:13693227701@163.com
基金资助:
国家自然科学基金资助项目(编号: 81570515)

Expression of Vaspin in HepG2 cells and in liver tissues of rats with nonalcoholic fatty liver diseases

Jiang Jiali, Li Li, Zhao Fei, et al

Department of Gastroenterology,Tongren Hospital,Affiliated to Capital Medical University,Beijing 100730,China

Received:2019-03-29 Online:2020-03-10 Published:2020-04-20

摘要/Abstract

摘要： 目的研究非酒精性脂肪性肝病(NAFLD)大鼠肝组织和体外培养的脂肪变性肝细胞Vaspin表达情况及其意义。方法采用随机数字表法随机将12只SD健康雄性大鼠分为模型组6只和对照组6只,分别采用Lieber-DeCarli 液体高脂饮食和标准饮食饲养7 w,建立模型或对照。采用免疫组织化学染色法检测肝组织Vaspin表达。采用油酸诱导法体外培养建立HepG2细胞脂肪变性模型,采用Western blot法检测细胞Vaspin蛋白表达。结果病理学检查提示脂肪变动物模型制备成功,表现为模型组肝细胞肿胀,细胞质内可见较多脂滴;模型组肝组织Vaspin表达增强,主要分布于脂滴周围;Western blot检测结果显示脂肪变性肝细胞和对照组细胞Vaspin/GAPDH表达分别为(0.49±0.70)和(0.68±0.40),差异显著 (P <0.05)。结论在NAFLD动物肝组织和体外培养的脂肪变性肝细胞Vaspin表达增强,可能通过影响脂滴形成而参与了NAFLD的发病。

关键词: 非酒精性脂肪性肝病, 内脏脂肪组织来源的丝氨酸蛋白酶抑制剂, 脂肪因子, HepG2细胞, 大鼠

Abstract: Objective The purpose of this study was to investigate the expression of visceral adipose tissue-derived serine protease inhibitor (Vaspin) in HepG2 cells and in liver tissues of rats with nonalcoholic fatty liver diseases (NAFD). Methods 12 Sprague-Dawley rats were randomly divided into model (n=6) and control group (n=6) by computer-generated numbers. The rats in the two groups were fed with high-fat diet (Lieber-DeCarli liquid high fat diet) and standard diet for 7 weeks respectively. The Vaspin expression was stained by immunohistochemical method. The HepG2 cells were induced by oleic acid to establish hepatocyte steatosis in vitro, and the expression of Vaspin protein in hepatocytes was detected by Western blot. Results The liver cells swollen in model group and many fat droplets were seen in cytoplasm of the cells, suggesting the cell model was successfully built up; the immunohistochemical staining showed that intensified expression of Vaspin in liver tissues of rats in the model,and the expression was mainly around the lipid droplet; the Western blot demonstrated that the Vaspin/GAPDH expression in steatotic hepatocytes and in control cells were (0.49±0.70) and (0.68±0.40), respectively (P<0.05). Conclusion Vaspin expression intensifies in steatotic hepatocytes and in liver tissues of rats with NAFLD, which might be involved in the pathogenesis of NAFLD, especially in lipid droplet formation.

Key words: Nonalcoholic fatty liver diseases, Visceral adipose tissue-derived serine protease inhibitor, Adipocyte factor, HepG2 cells, Rats

姜佳丽, 李莉, 赵菲, 钟乐萍, 郭子皓, 张川, 展玉涛. 非酒精性脂肪性肝病大鼠肝组织Vaspin表达及其意义探讨^*[J]. 实用肝脏病杂志, 2020, 23(2): 167-170.

Jiang Jiali, Li Li, Zhao Fei, et al. Expression of Vaspin in HepG2 cells and in liver tissues of rats with nonalcoholic fatty liver diseases[J]. Journal of Practical Hepatology, 2020, 23(2): 167-170.

参考文献

[1] Rinella M, Charlton M. The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health. Hepatology,2016,64(1):19-22.
[2] Kukla M, Zwirska K, Hartleb M. Serum chemerin and vaspin in non-alcoholic fatty liver disease. Scand J Gastroenterol,2010,45(2):235-242.
[3] Boutari C, Perakakis N, Mantzoros CS. Association of adipokines with development and progression of nonalcoholic fatty liver disease. Endocrinol Metab (Seoul), 2018 ,33(1):33-43.
[4] Dai R, Dong Z, Qian Y, et al. Obese type 2 diabetes mellitus patients have higher serum vaspin concentrations. J Diabetes, 2016,8(3):445-447.
[5] Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD).Metabolism, 2016 ,65(8):1038-1048.
[6] Paschos P, Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia, 2009,13(1):9-19.
[7] Feng R, Li Y, Wang C, et al. Higher vaspin levels in subjects with obesity and type 2 diabetes mellitus: a meta-analysis. Diabetes Res Clin Pract,2014,106(1):88-94.
[8] Li Z, Xue J, Chen P, et al. Prevalence of nonalcoholic fatty liver disease in mainland of China: a meta-analysis of published studies.J Gastroenterol Hepatol,2014,29(1):42-51.
[9] Blachier M, Leleu H, Peck-Radosavljevic M, et al. The burden of liver disease in Europe: a review of available epidemiological data. JHepatol, 2013,58(3): 593-608.
[10] Polyzos SA, Kountouras J, Anastasilakis AD, et,al. Irisin in patients with nonalcoholic fatty liver disease. Metabolism, 2014,63(2):207-217.
[11] Satheesh N. Nonalcoholic fatty liver disease from the perspective of an internist. Ochsner, 2002, 4(2): 92–97.
[12] Koliaki C, Roden M. Hepatic energy metabolism in human diabetes mellitus, obesity and non-alcoholic fatty liver disease. Mol Cell Endocrinol,2013,379(1-2):35-42.
[13] Kloting N, Berndt J, Kralisch S, et a1. Vaspin gene expression in human adipose tissue:association with obesity and type 2 diabetes.Biochem Biophys Res Commun,2006,339(1):430-436.
[14] Hida K,Wada J,Eguchi J,et a1. Visceral adipose tissue-derived serine protease inhibitor:a unique insulin sensitizing adipocytokine in obesity Vaspin gene expression in human adipose tissue:association with obesity and type 2 diabetes. Proc Natl Acad Sci U S A , 2005,102(1):10610-10615.
[15] Genc H, Dogru T, Tapan S, et al. Circulating vaspin and its relationship with insulin sensitivity, adiponectin, and liver histology in subjects with non-alcoholic steatohepatitis. Scand J Gastroenterol, 2011 ,46(11):1355-1361.
[16] Aktas B, Yilmaz Y, Eren F,et al. Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease. Metabolism,2011,60(4):544-549.
[17] Genc H, Dogru T, Tapan S, et al. Circulating vaspin and its relationship with insulin sensitivity, adiponectin, and liver histology in subjects with non-alcoholic steatohepatitis. Scand J Gastroenterol, 2011,46(11):1355-1361.
[18] Xu S, Zhang X, Liu P. Lipid droplet proteins and metabolic diseases. Biochim Biophys Acta Mol Basis Dis. 2018 ,1864(5 ):1968-1983.
[19] Rotonya M,Car Gr,Rexford S. Pathophysiology of lipid droplet proteins in liver diseases. Exp Cell Res, 2016,340 (2): 187–192.
[20] Gergana M, Deevska T, Mariana N, et al. The expanding role of sphingolipids in lipid droplet biogenesis. Biochim Biophys Acta Mol Cell Biol Lipids,2017,1862(10):1155-1165.

非酒精性脂肪性肝病大鼠肝组织Vaspin表达及其意义探讨^*

Expression of Vaspin in HepG2 cells and in liver tissues of rats with nonalcoholic fatty liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张猛, 陈晹, 刘娇, 李叶晟, 黄杨卿. 非酒精性脂肪性肝病小鼠肝组织与脂质代谢相关基因FAS、ACC和SREBP-1水平分析^*[J]. 实用肝脏病杂志, 2020, 23(2): 163-166.
[2]	黄橘村, 胡东辉, 张建军, 田德英. 慢病毒介导miR-203过表达对酒精性肝病大鼠肝损伤的保护作用及其机制研究^*[J]. 实用肝脏病杂志, 2020, 23(2): 171-174.
[3]	叶晓贤, 杨丽, 雷丽. 血清糖化血红蛋白和IL-6对非酒精性脂肪性肝病发病风险的预测价值探讨^*[J]. 实用肝脏病杂志, 2020, 23(2): 199-202.
[4]	贾晨, 张涛, 王浩, 戚凤君. 利拉鲁肽治疗非酒精性脂肪性肝病合并2型糖尿病患者血脂、血管内皮功能和肝纤维化指标的变化^*[J]. 实用肝脏病杂志, 2020, 23(2): 203-206.
[5]	刘继国, 窦翠云, 程广玲. NAFLD合并T2DM患者糖化血红蛋白和甲状腺激素水平的变化及其临床意义^*[J]. 实用肝脏病杂志, 2020, 23(2): 207-210.
[6]	曾震军, 李墨航. 血清学指标和脂肪肝指数诊断非酒精性脂肪性肝病价值分析^*[J]. 实用肝脏病杂志, 2020, 23(2): 211-214.
[7]	王丽娟, 朱兵兵, 胡敏华, 杨丽, 石莉红, 胡健薇. 匹伐他汀与阿托伐他汀治疗非酒精性脂肪性肝病患者疗效比较^*[J]. 实用肝脏病杂志, 2020, 23(2): 215-218.
[8]	任国亮, 李连生, 刘刚, 丰帆, 刘婧. 热量限制饮食对非酒精性脂肪性肝病患者胰岛素抵抗、血脂和氧化应激指标的影响^*[J]. 实用肝脏病杂志, 2020, 23(2): 219-222.
[9]	陈丽丽, 符茂雄, 蒙绪标, 方其超. 空腹C肽评估NAFLD合并T2DM患者肝纤维化进展价值分析^*[J]. 实用肝脏病杂志, 2020, 23(1): 38-41.
[10]	柳健, 朱峰发, 唐娟. 非均匀性脂肪肝患者腹部超声表现和血脂变化特点^*[J]. 实用肝脏病杂志, 2020, 23(1): 42-45.
[11]	魏重操, 刘娜, 邢欣, 澹台新兴, 杨倩, 蒋潇洒, 王进海. 多烯磷脂酰胆碱联合二甲双胍治疗非酒精性脂肪性肝病患者疗效和安全性Meta分析[J]. 实用肝脏病杂志, 2020, 23(1): 46-49.
[12]	毛重山, 殷辉, 肖二辉, 张英英. 非诺贝特对非酒精性脂肪性肝病合并2型糖尿病患者血脂、血管内皮功能和肝纤维化指标的影响^*[J]. 实用肝脏病杂志, 2020, 23(1): 50-53.
[13]	骆庆玲, 周永健, 唐文娟, 首第文, 黄红丽, 徐豪明, 黄惠康, 何杰, 杜艳蕾, 阮焕梅, 陈慧婷, 曹创裕. 移植NAFLD患者和健康人粪菌对高脂饮食大鼠肠道菌群的影响^*[J]. 实用肝脏病杂志, 2020, 23(1): 134-137.
[14]	郭化磊, 卜理琳, 裴颖, 殷宏振, 黄峰. 化浊通瘀汤干预非酒精性脂肪性肝病大鼠血清肿瘤坏死因子-α和瘦素的变化^*[J]. 实用肝脏病杂志, 2020, 23(1): 138-141.
[15]	任俞霏, 陈小青, 孔维宗, 王迎春. 丹酚酸B对非酒精性脂肪性肝病细胞模型自噬功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 804-807.